AffiliationDepartment of Endocrinology, St Bartholomew's Hospital, London, UK.
MetadataShow full item record
AbstractUnderstanding the mechanisms by which growth hormone (GH) interacts with its receptor has led to the design of compounds that function as GH receptor antagonists. One such compound has been conjugated to polyethylene glycol (PEG) to produce a drug, pegvisomant, which has been extensively investigated as a treatment for acromegaly. It was recently approved for clinical use in the US and will shortly be available on prescription in Europe. Studies have shown that the drug is able to normalize circulating levels of insulin-like growth factor-1 (IGF-1), the principal mediator of GH action, in 97% of patients with active acromegaly, as well as improve the symptoms and signs associated with GH excess. Serum IGF-1 levels have been used as the chief marker of efficacy of treatment with pegvisomant. The drug is able to achieve biochemical control in patients wholly or partially resistant to somatostatin analogs. Preliminary data suggests that pegvisomant may be a particularly suitable choice of medical therapy for patients with acromegaly and coexistent diabetes mellitus.
CitationClinical use of pegvisomant for the treatment of acromegaly. 2003, 2 (6):369-74 Treat Endocrinol
JournalTreatments in Endocrinology
- Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
- Authors: Paisley AN, Trainer P, Drake W
- Issue date: 2004 Mar
- Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
- Authors: Drake WM, Parkinson C, Besser GM, Trainer PJ
- Issue date: 2001 Nov
- Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
- Authors: Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G
- Issue date: 2008 Aug
- [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
- Authors: Zgliczyński W, Zdunowski P
- Issue date: 2007 Sep-Oct
- Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
- Authors: Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G
- Issue date: 2006 Mar